A Blood Stem Cell Transplant for Sickle Cell Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anemia, Sickle Cell
- Hemoglobinopathies
- Sickle Cell Disease
- Sickle Cell Disorder
- ? Thalassemia
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Both males and females
Description
This is a pilot study to determine the safety and feasibility of the COH-MC-17 regimen and ability of the regimen to induce a mixed chimeric status in severe sickle cell disease patients (hemoglobin SS or S-?º Thalassemia). The COH-MC-17 regimen consists of a non-myeloablative regimen (cyclophospham...
This is a pilot study to determine the safety and feasibility of the COH-MC-17 regimen and ability of the regimen to induce a mixed chimeric status in severe sickle cell disease patients (hemoglobin SS or S-?º Thalassemia). The COH-MC-17 regimen consists of a non-myeloablative regimen (cyclophosphamide, pentostatin and rabbit-anti-thymocyte globulin (ATG)) followed by a CD4+ T-cell-depleted haploidentical hematopoietic cell transplant (HaploHCT).
Tracking Information
- NCT #
- NCT03249831
- Collaborators
- California Institute for Regenerative Medicine (CIRM)
- Investigators
- Principal Investigator: Joseph Rosenthal, MD City of Hope Medical Center
Get Well Soon